Christopher Wallis: Hello, and thank you for joining us for this UroToday discussion of the NCCN clinical practice guidelines in oncology with a focus on the prostate cancer guidelines from February, 2021. Today, we’re discussing prostate cancer genetics. I’m Chris Wallis, an assistant professor in the Division of Urology at the University of Toronto, and […]
“So, what are your research plans after first year of fellowship?” My colleagues and I were frequently asked this question toward the closing months of our first year of hematology and oncology training, which focused primarily on outpatient clinical care at our academic medical center. I was reluctant to answer the question because the explanation […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana Farber Cancer Institute. I’m so excited to have here with me today, Professor Oliver Sartor, who is the Medical Director of the Tulane Cancer Center, as well as being the Laborde Family Professor of Cancer Research there in New […]
Thomas Keane: Good day, everybody. This is Tom Keane, coming to you from UroToday. And today, I think we have a very interesting topic. Of course, it’s metastatic castration-resistant prostate cancer, but the speaker is someone well known to most people in the field. It’s Professor Dan Petrylak, and he has very kindly agreed to […]
To determine whether higher coffee intake may reduce the risk of renal cell cancer (RCC) associated with lead (Pb) and other heavy metals with known renal toxicity. We conducted a nested case-control study of male smokers (136 RCC cases and 304 controls) within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.
The role of prostate-specific membrane antigen (PSMA)-targeted PET in comparison to mpMRI in the evaluation of intraprostatic cancer foci is not well defined. The aim of our study was to compare the diagnostic performances of PSMA PET/CT, mpMRI and PSMA PET/CT+mpMRI using 3 independent blinded readers for each modality and with histopathology as gold standard […]
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with 177Lu-PSMA-617 has shown promising results in patients with metastasized castration-resistant prostate cancer. We report a case of a 74-year-old man with metastatic prostate cancer with comorbidities of diabetes mellitus, hypertension, and chronic kidney disease.
Penile cancer (PeC) carcinogenesis is not fully understood, and no biomarkers are reported in clinical practice. We aimed to investigate molecular signatures based on miRNA and mRNA and perform an integrative analysis to identify molecular drivers and pathways for PeC development.
Localized prostate cancer (PCa) in patients is characterized by a dominant focus in the gland (dominant intraprostatic lesion, DIL). Accurate DIL identification may enable more accurate diagnosis and therapy through more precise targeting of biopsy, radiotherapy and focal ablative therapies.
The consensus conference of the International Society of Urological Pathology (ISUP), held in 2012, made recommendations regarding prognostic parameters of renal tumors. There was a strong consensus that tumor morphotype, pathologic tumor stage, and tumor grade are prognostic indicators of poor outcome.
